Clinical Relevance of Circulating, Cell-Free and Exosomal microRNAs in Plasma and Serum of Breast Cancer Patients

Schwarzenbach, Heidi

doi:10.1159/000478019

Cited by 62 publications

(51 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,4 Although all these components of liquid biopsies have advantages and limitations (for reviews, see refs. 20,21 ), the present review will focus on cfDNA. cfDNA carries information about the dynamics of cancer-specific genetic and epigenetic alterations.…”

Section: Introductionmentioning

confidence: 99%

Life and death of circulating cell-free DNA

Kustanovich

Schwartz

Peretz

et al. 2019

Cancer Biology & Therapy

407

386

View full text Add to dashboard Cite

Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of biomarkers for minimally invasive serial monitoring of treatment responses in cancer management. We will review the current understanding of the origin of circulating cell-free DNA and different forms of DNA release (including various types of cell death and active secretion processes) and clearance routes. The dynamics of extracellular DNA in blood during therapy and the role of circulating DNA in pathophysiological processes (tumor-associated inflammation, NETosis, and pre-metastatic niche development) provide insights into the mechanisms that contribute to tumor development and metastases formation. Better knowledge of circulating tumor-specific cell-free DNA could facilitate the development of new therapeutic and diagnostic options for cancer management. ARTICLE HISTORY

show abstract

Section: Introductionmentioning

confidence: 99%

Life and death of circulating cell-free DNA

Kustanovich

Schwartz

Peretz

et al. 2019

Cancer Biology & Therapy

407

386

View full text Add to dashboard Cite

show abstract

“…Other published results (118) suggest that exosome-mediated discharge of tumor-suppressor miRNA is selected in tumor evolution as a mechanism to organize the activation of a metastatic cascade (119). The load of exosomes is given for the parental cells and the circumstances in which they deliver them, which implies that circulating miRNAs in exosomes have the ability to serve as prognostic and predictive biomarkers (120).…”

Section: Exosomes Secreted From Mscs Have a Totally Different Effect mentioning

confidence: 99%

Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes

et al. 2020

View full text Add to dashboard Cite

“…Systemic therapies (hormones, cytotoxic agents, and others) and target‐based therapies (using antibodies or specific ligand/receptors) are the most common therapeutic strategies used for control and treatment of BC. Therapeutic choices and sequences depend on the BC stages and receptors . BC cells can develop resistance to these therapeutic agents by different mechanisms including extruding drugs by exosomes .…”

Section: Roles Of Exosomes In Breast Cancer Resistancementioning

confidence: 99%

Emerging roles of exosomal miRNAs in breast cancer drug resistance

Najminejad

Kalantar

Abdollahpour‐Alitappeh³

et al. 2019

IUBMB Life

View full text Add to dashboard Cite

Breast cancer (BC), as a heterogeneous disease, is considered as one of the most common malignancies in women worldwide. The resistance of BC cells to therapeutic agents has remained a big challenge in the treatment of BC patients. Some factors such as cytokines, exosomes, and soluble receptors were recognized as crucial agents involved in the development of drug resistance. However, the exact mechanisms underlying the drug resistance is still unknown. There is growing evidence to support the emerging roles of exosomes, especially exosomal miRNAs, in tumor initiation, angiogenesis, proliferation, migration, invasion, metastasis, and drug resistance. Therefore, identification of BC-specific exosomal miRNAs and their underlying mechanisms would be helpful to define sensitivity to therapeutic drugs and establish an appropriate therapeutic strategy. This review focuses mainly on the roles of exosomal miRNAs and their associated mechanisms in the resistance of BC cells to therapeutic agents, as well as critically examines the potential of these macromolecules as a treatment biomarker in BC patients. K E Y W O R D Sbreast cancer, exosomes, drug resistance, therapeutics, exosomal miRNA, microRNA 1 | INTRODUCTION Breast cancer (BC), after skin cancer, was reported to be the most common malignancy in women worldwide. 1 Conversely, BC was showed to have a low incidence rate in men, approximately 1%. BC does not kill in primary stage. It was shown that the 5-year survival rates are 99%, 84%, and 23% for women with localized BC, regional stage, and

show abstract

Clinical Relevance of Circulating, Cell-Free and Exosomal microRNAs in Plasma and Serum of Breast Cancer Patients

Cited by 62 publications

References 87 publications

Life and death of circulating cell-free DNA

Life and death of circulating cell-free DNA

Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes

Emerging roles of exosomal miRNAs in breast cancer drug resistance

Contact Info

Product

Resources

About